Back to Search Start Over

Smaller clinical trials for decision making; using p-values could be costly [version 1; referees: 1 approved with reservations]

Authors :
Nicholas Graves
Adrian G. Barnett
Edward Burn
David Cook
Author Affiliations :
<relatesTo>1</relatesTo>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, 4059, Australia<br /><relatesTo>2</relatesTo>Nuffield Department of Orthopaedics, Oxford University, Oxford, OX3 7LD, UK<br /><relatesTo>3</relatesTo>Princess Alexandra Hospital, Brisbane, Brisbane, QLD, 4102, Australia
Source :
F1000Research. 7:1176
Publication Year :
2018
Publisher :
London, UK: F1000 Research Limited, 2018.

Abstract

Background: Clinical trials might be larger than needed because arbitrary high levels of statistical confidence are sought in the results. Traditional sample size calculations ignore the marginal value of the information collected for decision making. The statistical hypothesis testing objective is misaligned with the goal of generating information necessary for decision-making. The aim of the present study was to show that a clinical trial designed to test a prior hypothesis against an arbitrary threshold of confidence may recruit too many participants, wasting scarce research dollars and exposing participants to research unnecessarily. Methods: We used data from a recent RCT powered for traditional rules of statistical significance. The data were also used for an economic analysis to show the intervention led to cost savings and improved health outcomes. Adoption represented a good investment for decision-makers. We examined the effect of reducing the trial’s sample size on the results of the statistical hypothesis-testing analysis and the conclusions that would be drawn by decision-makers reading the economic analysis. Results: As the sample size reduced it became more likely that the null hypothesis of no difference in the primary outcome between groups would fail to be rejected. For decision-makers reading the economic analysis, reducing the sample size had little effect on the conclusion about whether to adopt the intervention. There was always high probability the intervention reduced costs and improved health. Conclusions: Decision makers managing health services are largely invariant to the sample size of the primary trial and the arbitrary p-value of 0.05. If the goal is to make a good decision about whether the intervention should be adopted widely, then that could have been achieved with a much smaller trial. It is plausible that hundreds of millions of research dollars are wasted each year recruiting more participants than required for RCTs.

Details

ISSN :
20461402
Volume :
7
Database :
F1000Research
Journal :
F1000Research
Notes :
[version 1; referees: 1 approved with reservations]
Publication Type :
Academic Journal
Accession number :
edsfor.10.12688.f1000research.15522.1
Document Type :
research-article
Full Text :
https://doi.org/10.12688/f1000research.15522.1